Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer

Bibliography

• Cripps C, Winquist E, Devries MC, Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol 2010;17:37-48
   PubMed Web of Science ®Google Scholar
• Dias JD, Liikanen I, Guse K, Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1. Clin Cancer Res 2010;16:2540-9
   PubMed Web of Science ®Google Scholar
• Mehanna H, Jones TM, Gregoire V, Oropharyngeal carcinoma related to human papillomavirus. BMJ 2010;340:c1439
   PubMedGoogle Scholar
• Forastiere AA, Goepfert H, Maor M, Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. New Engl J Med 2003;349:2091-8
   PubMed Web of Science ®Google Scholar
• Donnelly OG, Errington-Mais F, Steele L, Measles virus causes immunogenic cell death in human melanoma. Gene Ther 2011; In press
   PubMed Web of Science ®Google Scholar
• Hu JC, Coffin RS, Davis CJ, A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006;12:6737-47
   PubMed Web of Science ®Google Scholar
• Senzer NN, Kaufman HL, Amatruda T, Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009;27:5763-71
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Hingorani M, Tanay MA, Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 2010;16:4005-15
   PubMed Web of Science ®Google Scholar
• Park BH, Hwang T, Liu TC, Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008;9:533-42
   PubMed Web of Science ®Google Scholar
• Liu TC, Hwang T, Park BH, The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008;16:1637-42
   PubMed Web of Science ®Google Scholar
• Heo J, Breitbach CJ, Moon A, Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther 2011;19:1170-9
   PubMed Web of Science ®Google Scholar
• Breitbach CJ, Burke J, Jonker D, Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011;477:99-102
   PubMed Web of Science ®Google Scholar
• Adams DJ, Ridinger DN, Spendlove RS, Protamine precipitation of two reovirus particle types from polluted waters. Appl Envir Microbiol 1982;44:589-96
   PubMed Web of Science ®Google Scholar
• Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. Am J Hyg 1963;77:29-37
   PubMed Web of Science ®Google Scholar
• Minuk GY, Paul RW, Lee PW. The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease. J Med Virol 1985;16:55-60
   PubMed Web of Science ®Google Scholar
• Tai JH, Williams JV, Edwards KM, Prevalence of reovirus-specific antibodies in young children in Nashville, Tennessee. J Infect Dis 2005;191:1221-4
   PubMed Web of Science ®Google Scholar
• van den Wollenberg DJM, van den Hengel SK, Dautzenberg IJC, A strategy for genetic modification of the spike-encoding segment of human reovirus T3D for reovirus targeting. Gene Ther 2008;15:1567-78
   PubMed Web of Science ®Google Scholar
• Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977;54:307-15
   PubMed Web of Science ®Google Scholar
• Duncan MR, Stanish SM, Cox DC. Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 1978;28:444-9
   PubMed Web of Science ®Google Scholar
• Strong JE, Lee PW. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 1996;70:612-16
   PubMed Web of Science ®Google Scholar
• Coffey MC, Strong JE, Forsyth PA, Reovirus therapy of tumors with activated Ras pathway. Science 1998;282:1332-4
   PubMed Web of Science ®Google Scholar
• Strong JE, Coffey MC, Tang D, The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998;17:3351-62
   PubMed Web of Science ®Google Scholar
• Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9
   PubMed Web of Science ®Google Scholar
• Rogers SJ, Harrington KJ, Rhys-Evans P, Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metast Rev 2005;24:47-69
   PubMed Web of Science ®Google Scholar
• Vorburger SA, Pataer A, Swisher SG, Genetically targeted cancer therapy: tumor destruction by PKR activation. Am J Pharmacogenomics 2004;4:189-98
   PubMedGoogle Scholar
• Meurs E, Chong K, Galabru J, Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 1990;62:379-90
   PubMed Web of Science ®Google Scholar
• Smakman N, van den Wollenberg DJ, Elias SG, KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2006;66:5403-8
   PubMed Web of Science ®Google Scholar
• Marcato P, Shmulevitz M, Pan D, Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther 2007;15:1522-30
   PubMed Web of Science ®Google Scholar
• Alain T, Kim TS, Lun X, Proteolytic disassembly is a critical determinant for reovirus oncolysis. Mol Ther 2007;15:1512-21
   PubMed Web of Science ®Google Scholar
• Comins C, Heinemann L, Harrington K, Reovirus: viral therapy for cancer 'as nature intended'. Clin Oncol (R Coll Radiol) 2008;20:548-54
   PubMed Web of Science ®Google Scholar
• Vidal L, Pandha HS, Yap TA, A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008;14:7127-37
   PubMed Web of Science ®Google Scholar
• Gollamudi R, Ghalib MH, Desai KK, Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 2010;28:641-9
   PubMed Web of Science ®Google Scholar
• Adair RA, Roulstone V, Scott KJ, Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Translat Med 2012;4:138ra77
   PubMed Web of Science ®Google Scholar
• Hirasawa K, Nishikawa SG, Norman KL, Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003;63:348-53
   PubMed Web of Science ®Google Scholar
• Qiao J, Wang H, Kottke T, Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 2008;14:259-69
   PubMed Web of Science ®Google Scholar
• Sobotkova E, Duskova M, Eckschlager T, Efficacy of reovirus therapy combined with cyclophosphamide and gene-modified cell vaccines on tumors induced in mice by HPV16-transformed cells. Int J Oncol 2008;33:421-6
   PubMed Web of Science ®Google Scholar
• Kottke T, Thompson J, Diaz RM, Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin Cancer Res 2009;15:561-9
   PubMed Web of Science ®Google Scholar
• White CL, Twigger KR, Vidal L, Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 2008;15:911-20
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Vile RG, Melcher A, Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev 2010;21:91-8
   PubMed Web of Science ®Google Scholar
• Comins C, Spicer J, Protheroe A, REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 2010;16:5564-72
   PubMed Web of Science ®Google Scholar
• Lolkema MP, Arkenau HT, Harrington K, A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 2011;17:581-8
   PubMed Web of Science ®Google Scholar
• Morris DG, Feng X, Difrancesco LM, REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors. Invest New Drugs 2012 (in press)
   Google Scholar
• Forsyth P, Roldan G, George D, A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008;16:627-32
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Melcher A, Vassaux G, Exploiting synergies between radiation and oncolytic viruses. Curr Opin Mol Ther 2008;10:362-70
   PubMed Web of Science ®Google Scholar
• Twigger K, Vidal L, White CL, Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res 2008;14:912-23
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Karapanagiotou EM, Roulstone V, Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 2010;16:3067-77
   PubMed Web of Science ®Google Scholar
• Kumar S, Gao L, Yeagy B, Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 2008;10:371-9
   PubMed Web of Science ®Google Scholar
• Pandha HS, Heinemann L, Simpson GR, Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res 2009;15:6158-66
   PubMed Web of Science ®Google Scholar
• Heinemann L, Simpson GR, Boxall A, Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer 2011;11:221
   PubMed Web of Science ®Google Scholar
• Roulstone V, Twigger K, Zaidi S, Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. Gene Ther 2012; In press
   PubMed Web of Science ®Google Scholar
• Karapanagiotou EM, Roulstone V, Twigger K, Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 2012;18:2080-9
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Reg 1984;22:27-55
   PubMedGoogle Scholar